An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Acadia Pharmaceuticals specializes in CNS therapies; a key insider recently trimmed their stake amid ongoing product pipeline developments.
Overview
James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals (NASDAQ:ACAD), disclosed the sale of 11,421 shares of common stock in an open-market transaction on June 26, 2026, according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average price ($26.08); post-transaction value based on June 26, 2026 market close price.
Details
*1-year price change calculated as of June 26, 2026.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.